<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38322108</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0034-6233</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>6</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Reumatologia</Title><ISOAbbreviation>Reumatologia</ISOAbbreviation></Journal><ArticleTitle>Autoimmunity and long COVID in children.</ArticleTitle><Pagination><StartPage>492</StartPage><EndPage>501</EndPage><MedlinePgn>492-501</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5114/reum/176464</ELocationID><Abstract><AbstractText>Numerous hypotheses regarding the pathogenetic mechanisms of long COVID have been proposed. Immune dysregulation and autoimmunity are among the leading hypotheses. In this article, we present two clinical cases of long COVID. The first case demonstrates the phenotype of long COVID with pain and musculoskeletal symptoms, which is often associated with autoimmunity and mimics systemic connective tissue diseases. In the second case, a high titer of antinuclear antibodies was observed after SARS-CoV-2 infection, but the clinical symptoms were limited to fever and headache. Only a comprehensive evaluation of clinical symptoms and thorough objective examination can confirm or exclude autoimmune diseases after a previous SARS-CoV-2 infection. A systematic search in the PubMed Medline database was carried out for studies focusing on immune dysregulation, autoimmunity, and its association with the clinical phenotype of long COVID. The question of the role of autoimmunity in the development of long COVID and the management approaches are discussed.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2023 Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boyarchuk</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-1234-0040</Identifier><AffiliationInfo><Affiliation>Department of Children's Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volianska</LastName><ForeName>Liubov</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5447-8059</Identifier><AffiliationInfo><Affiliation>Department of Children's Diseases and Pediatric Surgery, I. Horbachevsky Ternopil National Medical University, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>Reumatologia</MedlineTA><NlmUniqueID>20130190R</NlmUniqueID><ISSNLinking>0034-6233</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">immune dysregulation</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-COVID-19 condition</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>7</Day><Hour>3</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38322108</ArticleId><ArticleId IdType="pmc">PMC10839920</ArticleId><ArticleId IdType="doi">10.5114/reum/176464</ArticleId><ArticleId IdType="pii">176464</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21: 133&#x2013;146, DOI: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsilingiris D, Vallianou NG, Karampela I, et al. . Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges. Int J Mol Sci 2023; 24: 10458, DOI: 10.3390/ijms241310458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310458</ArticleId><ArticleId IdType="pmc">PMC10341908</ArticleId><ArticleId IdType="pubmed">37445634</ArticleId></ArticleIdList></Reference><Reference><Citation>National Research Action Plan on Long-COVID. Available at: https://www.covid.gov/assets/files/National-Research-Action-Plan-on-Long-COVID-08012022.pdf.</Citation></Reference><Reference><Citation>WHO: Post COVID-19 Condition (Long COVID). Available at: https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition#:~:text=It%20is%20defined%20as%20the,months%20with%20no%20other%20explanation (Access: 11.07.2023).</Citation></Reference><Reference><Citation>CDC: Long COVID or Post-COVID Conditions. Available at: https://www.cdc.gov/coronavirus/2019-ncov/long-termeffects/index.html#:~:text=Long%20COVID%20is%20broadly%20defined,with%20CDC%20and%20other%20partners (Access: 06.07.2023).</Citation></Reference><Reference><Citation>NICE: COVID-19 Rapid Guideline: Managing the Longterm Effects of COVID-19. Available at: https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742#:~:text=In%20addition%20to%20the%20clinical,)%20and%20post%E2%80%91COVID%E2%80%9119 (Access: 06.07.2023).</Citation></Reference><Reference><Citation>Stephenson T, Allin B, Nugawela MD, et al. . Long COVID (post-COVID-19 condition) in children: a modified Delphi process. Arch Dis Child 2022; 107: 674&#x2013;680, DOI: 10.1136/archdischild-2021-323624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2021-323624</ArticleId><ArticleId IdType="pmc">PMC8983414</ArticleId><ArticleId IdType="pubmed">35365499</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019, DOI: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Izquierdo-Pujol J, Moron-Lopez S, Dalmau J, et al. . Post COVID-19 Condition in Children and Adolescents: An Emerging Problem. Front Pediatr 2022; 10: 894204, DOI: 10.3389/fped.2022.894204.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2022.894204</ArticleId><ArticleId IdType="pmc">PMC9130634</ArticleId><ArticleId IdType="pubmed">35633949</ArticleId></ArticleIdList></Reference><Reference><Citation>Borch L, Holm M, Knudsen M, et al. . Long COVID symptoms and duration in SARS-CoV-2 positive children &#x2013; a nationwide cohort study. Eur J Pediatr 2022; 181: 1597&#x2013;1607, DOI: 10.1007/s00431-021-04345-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-021-04345-z</ArticleId><ArticleId IdType="pmc">PMC8742700</ArticleId><ArticleId IdType="pubmed">35000003</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, Townsend L, Savinelli S, Mallon PWG. Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets. Front Mol Biosci 2023; 10: 1157651, DOI: 10.3389/fmolb.2023.1157651.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2023.1157651</ArticleId><ArticleId IdType="pmc">PMC10171433</ArticleId><ArticleId IdType="pubmed">37179568</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond B, Lipsky PE. Autoimmunity and Autoimmune Diseases. In: Jameson J, Fauci AS, Kasper DL, et al.. (eds.). Harrison&#x2019;s Principles of Internal Medicine, 20e. McGraw Hill; 
2018. Available at: https://accessmedicine.mhmedical.com/content.aspx?bookid=2129&amp;sectionid=188731488 (Access: 29.07.2023).</Citation></Reference><Reference><Citation>Boyarchuk O, Predyk L, Yuryk I. COVID-19 in patients with juvenile idiopathic arthritis: frequency and severity. Reumatologia 2021; 59: 197&#x2013;199, DOI: 10.5114/reum.2021.107590.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2021.107590</ArticleId><ArticleId IdType="pmc">PMC8436806</ArticleId><ArticleId IdType="pubmed">34538947</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarchuk O, Kovalchuk T. Overlapping clinical features of systemic juvenile idiopathic arthritis and SARS-CoV-2-related multisystem inflammatory syndrome in children. Reumatologia 2023; 61: 63&#x2013;70, DOI: 10.5114/reum/161185.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum/161185</ArticleId><ArticleId IdType="pmc">PMC10044031</ArticleId><ArticleId IdType="pubmed">36998579</ArticleId></ArticleIdList></Reference><Reference><Citation>Garmendia JV, Garc&#xed;a AH, De Sanctis CV, et al. . Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. Curr Issues Mol Biol 2022; 45: 33&#x2013;50, DOI: 10.3390/cimb45010003.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cimb45010003</ArticleId><ArticleId IdType="pmc">PMC9857622</ArticleId><ArticleId IdType="pubmed">36661489</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Caricchio R, Casanova JL, et al. . The intersection of COVID-19 and autoimmunity. J Clin Invest 2021; 131: e154886, DOI: 10.1172/JCI154886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI154886</ArticleId><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A, Manns MP, Strassburg CP. Autoimmunity and viruses. Clin Liver Dis 2002; 6: 739&#x2013;753, DOI: 10.1016/s1089-3261(02)00024-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1089-3261(02)00024-7</ArticleId><ArticleId IdType="pubmed">12362578</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti MK, Cyprian FS, Nasrallah GK, et al. . Viruses and Autoimmunity: A Review on the Potential Interaction and Molecular Mechanisms. Viruses 2019; 11: 762, DOI: 10.3390/v11080762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v11080762</ArticleId><ArticleId IdType="pmc">PMC6723519</ArticleId><ArticleId IdType="pubmed">31430946</ArticleId></ArticleIdList></Reference><Reference><Citation>Getts DR, Chastain EML, Terry RL, Miller SD. Virus infection, antiviral immunity, and autoimmunity. Immunol Rev 2013; 255: 197&#x2013;209, DOI: 10.1111/imr.12091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12091</ArticleId><ArticleId IdType="pmc">PMC3971377</ArticleId><ArticleId IdType="pubmed">23947356</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujinami RS, Von Herrath MG, Christen U, Whitton JL. Molecular Mimicry, Bystander Activation, or Viral Persistence: Infections and Autoimmune Disease. Clin Microbiol Rev 2006; 19: 80&#x2013;94, DOI: 10.1128/CMR.19.1.80-94.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.19.1.80-94.2006</ArticleId><ArticleId IdType="pmc">PMC1360274</ArticleId><ArticleId IdType="pubmed">16418524</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt&#x2019;s lymphoma. EMBO J 2002; 21: 954&#x2013;965, DOI: 10.1093/emboj/21.5.954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.5.954</ArticleId><ArticleId IdType="pmc">PMC125896</ArticleId><ArticleId IdType="pubmed">11867523</ArticleId></ArticleIdList></Reference><Reference><Citation>Draborg AH, Duus K, Houen G. Epstein-Barr Virus in Systemic Autoimmune Diseases. Clin Dev Immunol 2013; 2013: 5738, DOI: 10.1155/2013/535738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/535738</ArticleId><ArticleId IdType="pmc">PMC3766599</ArticleId><ArticleId IdType="pubmed">24062777</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarchuk O. The correlation between cytokine concentrations and IgG/IgM antibodies to viruses of the Herpesviridae family in children with rheumatic heart disease. Paediatr Croat 2021; 65: 53&#x2013;58. DOI: 10.13112/PC.2021.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.13112/PC.2021.9</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen MA, van den Heuvel D, van der Zwet KV, et al. . Herpesvirus Infections and Transglutaminase Type 2 Antibody Positivity in Childhood: The Generation R Study. J Pediatr Gastroenterol Nutr 2016; 63: 423&#x2013;430, DOI: 10.1097/MPG.0000000000001163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MPG.0000000000001163</ArticleId><ArticleId IdType="pubmed">26881413</ArticleId></ArticleIdList></Reference><Reference><Citation>Christen U, Von Herrath MG. Infections and autoimmunity &#x2013; good or bad? J Immunol 2005; 174: 7481&#x2013;7486, DOI: 10.4049/jimmunol.174.12.7481.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.12.7481</ArticleId><ArticleId IdType="pubmed">15944245</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay CM, Stefanska AM, Walsh KP, et al. . Helminth Products Protect against Autoimmunity via Innate Type 2 Cytokines IL-5 and IL-33, Which Promote Eosinophilia. J Immunol 2016; 196: 703&#x2013;714, DOI: 10.4049/jimmunol.1501820.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501820</ArticleId><ArticleId IdType="pubmed">26673140</ArticleId></ArticleIdList></Reference><Reference><Citation>Filosto M, Cotti Piccinelli S, Gazzina S, et al. . Guillain-Barr&#xe9; syndrome and COVID-19: A 1-year observational multicenter study. Eur J Neurol 2022; 29: 3358&#x2013;3367, DOI: 10.1111/ene.15497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15497</ArticleId><ArticleId IdType="pmc">PMC9349567</ArticleId><ArticleId IdType="pubmed">35837806</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun 2020; 3: 100051, DOI: 10.1016/j.jtauto.2020.100051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100051</ArticleId><ArticleId IdType="pmc">PMC7142689</ArticleId><ArticleId IdType="pubmed">32292901</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Rumeileh S, Abdelhak A, Foschi M, et al. . Guillain-Barr&#xe9; syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J Neurol 2021; 268: 1133&#x2013;1170, DOI: 10.1007/s00415-020-10124-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10124-x</ArticleId><ArticleId IdType="pmc">PMC7445716</ArticleId><ArticleId IdType="pubmed">32840686</ArticleId></ArticleIdList></Reference><Reference><Citation>Zacharias H, Dubey S, Koduri G, D&#x2019;Cruz D. Rheumatological complications of Covid-19. Autoimmun Rev 2021; 20: 102883, DOI: 10.1016/j.autrev.2021.102883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102883</ArticleId><ArticleId IdType="pmc">PMC8256657</ArticleId><ArticleId IdType="pubmed">34237419</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Brito-Zer&#xf3;n P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 2021; 17: 315&#x2013;332, DOI: 10.1038/s41584-021-00608-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-021-00608-z</ArticleId><ArticleId IdType="pmc">PMC8072739</ArticleId><ArticleId IdType="pubmed">33903743</ArticleId></ArticleIdList></Reference><Reference><Citation>Gracia-Ramos AE, Martin-Nares E, Hern&#xe1;ndez-Molina G. New Onset of Autoimmune Diseases Following COVID-19 Diagnosis. Cells 2021; 10: 3592, DOI: 10.3390/cells10123592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123592</ArticleId><ArticleId IdType="pmc">PMC8700122</ArticleId><ArticleId IdType="pubmed">34944099</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Stobbione P, et al. . SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci 2021; 14: 898&#x2013;907, DOI: 10.1111/cts.12953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12953</ArticleId><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Han T, Chen J, et al. . Clinical and autoimmune characteristics of severe and clinical cases of COVID-19. Clin Transl Sci 2020; 13: 1077&#x2013;1086, DOI: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachoyiannopoulos PG, Magira E, Alexopoulos H, et al. . Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis 2020; 79: 1661&#x2013;1663, DOI: 10.1136/annrheumdis-2020-218009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218009</ArticleId><ArticleId IdType="pubmed">32581086</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Gervais A, Le Voyer T, et al. . Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci Immunol 2021; 6: eabl4340, DOI: 10.1126/sciimmunol.abl4340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abl4340</ArticleId><ArticleId IdType="pmc">PMC8521484</ArticleId><ArticleId IdType="pubmed">34413139</ArticleId></ArticleIdList></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, et al. . Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis 2022; 74: 1191&#x2013;1198, DOI: 10.1093/cid/ciab611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Guest PC, Neyazi A, Braun-Dullaeus RC, et al. . A Molecular Biomarker-Based Triage Approach for Targeted Treatment of Post-COVID-19 Syndrome Patients with Persistent Neurological or Neuropsychiatric Symptoms. Adv Exp Med Biol 2023; 1412: 97&#x2013;115, DOI: 10.1007/978-3-031-28012-2_5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-031-28012-2_5</ArticleId><ArticleId IdType="pubmed">37378763</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Boppana S, Perez MD, et al. . Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest 2021; 131: e140491, DOI: 10.1172/JCI140491.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140491</ArticleId><ArticleId IdType="pmc">PMC7773371</ArticleId><ArticleId IdType="pubmed">33119547</ArticleId></ArticleIdList></Reference><Reference><Citation>Taeschler P, Adamo S, Deng Y, et al. . T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19. Allergy 2022; 77: 2468&#x2013;2481, DOI: 10.1111/all.15372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15372</ArticleId><ArticleId IdType="pmc">PMC9347640</ArticleId><ArticleId IdType="pubmed">35567391</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23: 210&#x2013;216, DOI: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva Andrade B, Siqueira S, de Assis Soares WR, et al. . Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses 2021; 13: 700, DOI: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al. . Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Infect Dis 2021; 224: 1839&#x2013;1848, DOI: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>George PM, Reed A, Desai SR, et al. . A persistent neutrophil-associated immune signature characterizes post-COVID-19 pulmonary sequelae. Sci Transl Med 2022; 14: eabo5795, DOI: 10.1126/scitranslmed.abo5795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abo5795</ArticleId><ArticleId IdType="pubmed">36383686</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, et al. . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27: 1205&#x2013;1211, DOI: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G, Diodati F, Puntoni M, et al. . Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11: 1541, DOI: 10.3390/jcm11061541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881&#x2013;895.e20, DOI: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Mitchell A, Wang CY, et al. . Low Prevalence of Interferon &#x3b1; Autoantibodies in People Experiencing Symptoms of Post-Coronavirus Disease 2019 (COVID-19) Conditions, or Long COVID. J Infect Dis 2023; 227: 246&#x2013;250, DOI: 10.1093/infdis/jiac372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac372</ArticleId><ArticleId IdType="pmc">PMC9494362</ArticleId><ArticleId IdType="pubmed">36089700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28: 2398&#x2013;2405, DOI: 10.1038/s41591-022-02051-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02051-3</ArticleId><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Im JH, Chung MH, Park YK, et al. . Antinuclear antibodies in infectious diseases. Infect Dis (Lond) 2020; 52: 177&#x2013;185, DOI: 10.1080/23744235.2019.1690676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2019.1690676</ArticleId><ArticleId IdType="pubmed">31718355</ArticleId></ArticleIdList></Reference><Reference><Citation>Grygiel-G&#xf3;rniak B, Rogacka N, Puszczewicz M. Antinuclear antibodies in healthy people and non-rheumatic diseases &#x2013; diagnostic and clinical implications. Reumatologia 2018; 56: 243&#x2013;248, DOI: 10.5114/reum.2018.77976.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2018.77976</ArticleId><ArticleId IdType="pmc">PMC6142026</ArticleId><ArticleId IdType="pubmed">30237629</ArticleId></ArticleIdList></Reference><Reference><Citation>Volianska L, Burbela E, Kosovska T, et al. . The role of vitamin D in the course of SARS-CoV-2 infection and long COVID in children (literature review). Child&#x2019;s Health 2023; 18: 225&#x2013;230, DOI: 10.22141/2224-0551.18.3.2023.1590.</Citation><ArticleIdList><ArticleId IdType="doi">10.22141/2224-0551.18.3.2023.1590</ArticleId></ArticleIdList></Reference><Reference><Citation>Fawzy NA, Abou Shaar B, Taha RM, et al. . A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform. Clin Microbiol Infect 2023; 29: 570&#x2013;577, DOI: 10.1016/j.cmi.2023.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.01.007</ArticleId><ArticleId IdType="pmc">PMC9837206</ArticleId><ArticleId IdType="pubmed">36642173</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Sivan M, Delaney B, et al. . Long COVID &#x2013; an update for primary care. BMJ 2022; 378: e072117, DOI: 10.1136/bmj-2022-072117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072117</ArticleId><ArticleId IdType="pubmed">36137612</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnigan LEM, Cassar MP, Koziel MJ, et al. . Efficacy and tolerability of an endogenous metabolic modulator (AXA1125) in fatigue-predominant long COVID: a single-centre, double-blind, randomised controlled phase 2a pilot study. EClinicalMedicine 2023; 59: 101946, DOI: 10.1016/j.eclinm.2023.101946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101946</ArticleId><ArticleId IdType="pmc">PMC10102537</ArticleId><ArticleId IdType="pubmed">37223439</ArticleId></ArticleIdList></Reference><Reference><Citation>Chadda KR, Blakey EE, Huang CL, Jeevaratnam K. Long COVID-19 and postural orthostatic tachycardia syndrome &#x2013; is dysautonomia to be blamed? Front Cardiovasc Med 2022; 9: 860198, DOI: 10.3389/fcvm.2022.860198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.860198</ArticleId><ArticleId IdType="pmc">PMC8959615</ArticleId><ArticleId IdType="pubmed">35355961</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng LN, Bonilla HF, Shafer RW, et al. . The Use of Nirmatrelvir-ritonavir in a Case of Breakthrough Long COVID. Explor Res Hypothesis Med 2023, DOI: 10.14218/ERHM.2022.00045.</Citation><ArticleIdList><ArticleId IdType="doi">10.14218/ERHM.2022.00045</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Lin F, et al. . Association of Nirmatrelvir/Ritonavir Treatment with Long COVID Symptoms in an Online Cohort of Non-Hospitalized Individuals Experiencing Breakthrough SARS-CoV-2 Infection in the Omicron Era. medRxiv 2023, DOI: 10.1101/2023.03.02.23286730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.03.02.23286730</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante CT, Buse JB, Liebovitz D, et al. . Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of long COVID over 10-month follow-up. medRxiv 2022: 2022.12.21.22283753, DOI: 10.1101/2022.12.21.22283753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.12.21.22283753</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. . Functional autoanti-bodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun 2021; 4: 100100, DOI: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>